Immunotherapy

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.

What is Immunotherapy?

Immunotherapy is a treatment that is designed to harness the ability of the body’s immune system to combat infection or disease.

Activation Immunotherapies

Immunotherapy and Helminthic Therapy

Suppression Immunotherapies

Immunotherapy: Past, Present and Future

Adoptive T Cell Therapy Methodology

Adoptive T Cell Therapy Applications

Immunotherapy: The Future of Lung Cancer Treatment?

Neoantigens' Role in Immunotherapy

Latest Immunotherapy News and Research

Overcoming cancer relapse with CAR-Enhancer therapy

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.

26 Jul 2024

Electrical currents could supercharge cancer-killing immune cells, study finds

Scientists have discovered that electrical currents may make Natural Killer (NK) cells – our very own cancer-killing immune cells – even better killers, which could have significant implications for treating some cancers.

25 Jul 2024

Fecal microbiota transplants can boost the effectiveness of immunotherapy in gastrointestinal cancers

Findings from a small, proof-of-concept clinical trial have suggested that fecal microbiota transplants (FMTs) can boost the effectiveness of immunotherapy in a range of gastrointestinal cancers.

25 Jul 2024

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.

25 Jul 2024

Simple blood test may predict CAR-T therapy success in multiple myeloma

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research from Weill Cornell Medicine, NewYork-Presbyterian, Columbia University and Icahn School of Medicine at Mount Sinai.

24 Jul 2024

Breakthrough research identifies fibrin as key factor in preterm brain bleeds

Mark Petersen, MD, has seen firsthand the devastating effects of brain bleeds in premature babies. It's an exceedingly common condition that affects up to 20 percent of infants born before 28 weeks of gestation, bringing an increased risk for developmental delays and autism.

24 Jul 2024

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study from investigators at the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center.

19 Jul 2024

Physical modulation of the tumor microenvironment to enhance cancer therapy

Announcing a new article publication for BIO Integration journal. The tumor microenvironment (TME) has a crucial role in tumor development, metastasis, and recurrence.

19 Jul 2024

FDA approval of lifileucel: A milestone in tumor-infiltrating lymphocyte therapy for advanced melanoma

The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer therapy.

18 Jul 2024

$Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia$

Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia

Relapsed/refractory acute myeloid leukemia (AML), a so-called blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient's organ functions.

18 Jul 2024

Harnessing cell's natural delivery system for targeted drug delivery

Each cell in the body has its own unique delivery system that scientists are working on harnessing to move revolutionary biological drugs -; molecules like proteins, RNA and combinations of the two -; to specific diseased parts of the body.

17 Jul 2024

Researchers discover key functions of IRF1 in cancer progression and treatment response

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have uncovered new details about the role of a protein called interferon regulatory factor (IRF1) in cancer progression and treatment response, offering new insight that can potentially help improve the effectiveness of cancer immunotherapy.

15 Jul 2024

Triad of immune cells key to successful cancer immunotherapy, study finds

There's a frustrating fact about today's immunotherapies for cancer. While sometimes they work beautifully -; completely eliminating or greatly reducing cancer in particular patients -; other times they don't work at all. It's a mystery.

15 Jul 2024

Immunotherapy response assessment in malignant pleural mesothelioma: FDG-PET/CT vs. CT

A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma."

15 Jul 2024

ARPA-H funding boosts Wyss Institute's RNA therapeutic project

With the award for up to $27 million from the Advanced Research Projects Agency for Health (ARPA-H), a collaborative research project at the Wyss Institute for Biologically Inspired Engineering at Harvard University will advance a disease-agnostic novel RNA therapeutic with the potential to treat diverse diseases, and to be effectively and rapidly deployable.

15 Jul 2024

Antibody-drug conjugate shows preclinical efficacy

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Entering the golden age for antibody-drug conjugates in gynecologic cancer."

13 Jul 2024

Inulin gel-based oral immunotherapy is effective in suppressing food allergy responses and anaphylactic shock

A novel oral immunotherapy platform that uses formulated inulin gel combined with food allergens to orally deliver dietary antigens.

12 Jul 2024

Cellular immunotherapy offers hope for solid tumors

Early findings from a small clinical trial provide evidence that a new cellular immunotherapy approach may be effective in treating metastatic solid tumors. In the trial, researchers from the National Institutes of Health (NIH) genetically engineered normal white blood cells, known as lymphocytes, from each patient to produce receptors that recognize and attack their specific cancer cells.

12 Jul 2024

Distinct T-cell signatures identified in children with type 1 diabetes

A study conducted at the University of Eastern Finland found distinct signatures in CD8-positive T cells in blood samples from children with newly diagnosed type 1 diabetes and in autoantibody-positive children who later developed type 1 diabetes.

11 Jul 2024

CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma

CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven't experienced improvement with chemotherapy treatments.

11 Jul 2024